BIO3CBD Trademark

Trademark Overview


On Thursday, February 7, 2019, a trademark application was filed for BIO3CBD with the United States Patent and Trademark Office. The USPTO has given the BIO3CBD trademark a serial number of 88292621. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, October 13, 2020. This trademark is owned by Boston BioPharm, Inc.. The BIO3CBD trademark is filed in the Pharmaceutical Products category with the following description:

dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietary and nutritional supplements featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ...
bio3cbd

General Information


Serial Number88292621
Word MarkBIO3CBD
Filing DateThursday, February 7, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, October 13, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicesdietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietary and nutritional supplements featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease
Pseudo MarkBIO THREE CBD

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 1, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBoston BioPharm, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouthlake, TX 76092

Trademark Events


Event DateEvent Description
Tuesday, October 13, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, October 13, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, March 24, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, March 24, 2020FINAL REFUSAL E-MAILED
Tuesday, March 24, 2020FINAL REFUSAL WRITTEN
Wednesday, March 11, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 11, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 11, 2020ASSIGNED TO LIE
Thursday, March 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 12, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 12, 2019NON-FINAL ACTION E-MAILED
Thursday, September 12, 2019NON-FINAL ACTION WRITTEN
Monday, September 9, 2019ASSIGNED TO EXAMINER
Thursday, March 7, 2019ASSIGNED TO EXAMINER
Friday, March 1, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 11, 2019NEW APPLICATION ENTERED IN TRAM